Allegion (NYSE: ALLE) Reports Q4, Full-Year 2025 Financial Results, Introduces 2026 Outlook February 17, 2026 High-Single Digit Revenue Growth for the Enterprise and Continued Strength in Americas Non-Residential Quarterly Financial Highlights (All comparisons are year-over-year, unless otherwise noted) Net earnings per share (EPS) of $1.70, up 3.0% compared with $1.65; Adjusted EPS of $1.94, up 4.3% compared with $1.86 Revenues of $1,033.2 million, up 9.3% on a reported basis and up 3.3% on an organic basis Operating margin of 20.3%, compared with 19.5%; Adjusted operating margin of 22.4%, compared with 22.1% Full-Year Financial Highlights (All comparisons are year-over-year, unless otherwise noted) EPS of $7.44, up 9.1% compared with $6.82; Adjusted EPS of $8.14, up 8.1% compared with $7.53 Revenues of $4,067.3 million, up 7.8% on a reported basis and up 4.1% on an organic basis Operating margin of 21.1%, compared with 20.7%; Adjusted operating margin of 23.2%, up 40 basis points compared with 22.8% Available cash flow, which is defined as net cash from operating activities minus capital expenditures, was $685.7 million for 2025, an increase of 17.6% 2026 Full-Year Outlook Highlights Full-year reported revenue growth is estimated to be 5% to 7%, with organic revenue growth estimated to be 2% to 4% Full-year adjusted EPS is estimated to be $8.70 to $8.90 Available cash flow is estimated to be 85% to 95% of adjusted net income
Antofagasta’s shares dip despite soaring revenue February 17, 2026 London listed Mining company Antofagasta saw its share’s dip in early morning trading despite reporting a rise in revenue, driven by increased commodity prices and booming demand. The Chilean based group recorded a 30 per cent jump in revenue to $8.6bn (£6.3bn), reflecting copper prices reaching record highs in 2025, coupled with the rising prices [...]
Lloyds offloads Scottish Widows Europe in £100m deal February 17, 2026 Lloyds Banking Group has offloaded its European life insurance business to FTSE 250 firm Chesnara in the latter’s second major deal with a UK bank. The FTSE 100 banking giant – which posted a hefty profit jump last month for the 2025 financial year – has inked a €110m (£96m) deal with Chesnara for Luxembourg-based [...]
‘What if a blind person falls over an e-bike?’: The untenable rise of whataboutism February 17, 2026 Rowing about hypothetical dangers like e-bikes on pavements is turning London into a febrile City, scared of progress, writes Michael Martins.
Annabel’s profit trebles as Mayfair club defies hospitality gloom February 16, 2026 One of London’s best-known private members clubs has shrugged off wider hospitality gloom after posting a near-tripling of profit. Mayfair-based Annabel’s, which has been based on Berkeley Square since the 1960s, toasted a pre-tax profit of £12.4m in the year to January 2025, a rise of 184 per cent on the previous year. Revenue over [...]
Youri Djorkaeff on investing, SailGP and buying an English football club February 16, 2026 French football legend Youri Djorkaeff and his son Sacha on their investment vehicle Playmaker, backing SailGP and buying an English club. Two years after helping his country to win a home World Cup in 1998, Youri Djorkaeff was ticking off another life goal in France colours. Only this time it was on the waters around [...]
K2 Partnering Solutions Appoints Srinivas Rao as Chief Executive Officer February 16, 2026 K2 Partnering Solutions, a global leader in consultative technology and talent solutions, today announced the appointment of Srinivas Rao as Chief Executive Officer. Srinivas is a seasoned global executive with more than 28 years of experience driving value creation, scalable growth, and operational transformation across digital, consulting, IT services, and business services. He brings deep [...]
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday February 16, 2026 A new post-hoc analysis from the LIBERTY studies, presented at ECCO 2026, demonstrated that initiating subcutaneous (SC) infliximab (Remsima™ SC) after a treatment interruption following intravenous (IV) infliximab induction helps patients with Crohn’s disease (CD) and ulcerative colitis (UC) recapture and maintain disease control1 The results demonstrated that SC infliximab provides an effective and safe option to regain clinical control after a planned or unplanned treatment interruption More than a total of 30 accepted abstracts including one oral and one digital oral presentation and eight posters, reinforce Celltrion’s commitment to inflammatory bowel disease (IBD) research aimed at enhancing patient outcomes
Oak Furnitureland pares back losses as firm eyes showroom expansion February 16, 2026 Oak Furnitureland is eyeing further showroom expansion after the retailer improved its profitability. The Swindon-based business is targeting a host of new stores over the course of 2026 following the opening of a new showroom in Coventry in September, and is eyeing a refurbishment of at least half of its existing store estate by the [...]
Greene King weighs job cuts as pub sector braces for cost squeeze February 15, 2026 Greene King is preparing to cut around 100 roles as Britain’s second-largest pub operator reviews its cost base against a backdrop of rising taxes and mounting pressure across the hospitality sector. The brewer and pub group, which operates roughly 2,600 sites across the UK, is understood to be assessing changes to its head office and [...]